(Q35121620)

6 August 2017

1 reference

title

Novel therapies in multiple myeloma (English)

1 reference

6 August 2017

Novel Therapies in Multiple Myeloma (English)

1 reference

30 December 2023

author name string

Seema Singhal

series ordinal

1

1 reference

6 August 2017

Jayesh Mehta

series ordinal

2

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12731664

30 December 2023

publication date

1 April 2003

1 reference

full work available at URL

6 August 2017

https://link.springer.com/article/10.1007/BF02983778/fulltext.html

1 reference

https://link.springer.com/content/pdf/10.1007/BF02983778.pdf

30 December 2023

file format

Portable Document Format

1 reference

http://link.springer.com/content/pdf/10.1007/BF02983778

30 December 2023

1 reference

International Journal of Hematology

30 December 2023

published in

1 reference

6 August 2017

77

1 reference

6 August 2017

3

1 reference

6 August 2017

226-231

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02983778

6 August 2017

0 references

cites work

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

1 reference

12 December 2020

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

12 December 2020

Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone

1 reference

12 December 2020

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

12 December 2020

Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug

1 reference

12 December 2020

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

1 reference

12 December 2020

Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus

1 reference

12 December 2020

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

1 reference

12 December 2020

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

1 reference

12 December 2020

Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma

1 reference

12 December 2020

Thalidomide treatment of resistant or relapsed multiple myeloma patients

1 reference

12 December 2020

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

12 December 2020

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

12 December 2020

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

1 reference

12 December 2020

Immunotherapeutic and antitumour potential of thalidomide analogues

1 reference

12 December 2020

Thalidomide in refractory and relapsing multiple myeloma

1 reference

12 December 2020

Thalidomide in cancer

1 reference

12 December 2020

Thalidomide in patients with advanced multiple myeloma

1 reference

12 December 2020

Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma

1 reference

12 December 2020

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

1 reference

12 December 2020

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

12 December 2020

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

1 reference

12 December 2020

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

12 December 2020

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma

1 reference

12 December 2020

Thalidomide is an inhibitor of angiogenesis

1 reference

12 December 2020

Bone marrow angiogenesis and progression in multiple myeloma.

1 reference

12 December 2020

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

12 December 2020

Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative

1 reference

12 December 2020

Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations.

1 reference

12 December 2020

The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus

1 reference

12 December 2020

Inhibition of IL-12 production by thalidomide

1 reference

12 December 2020

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

12 December 2020

Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis.

1 reference

12 December 2020

Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells

1 reference

12 December 2020

27

86

404

M Hus

2001

1 reference

30 December 2023

28

87

408

P Tosi

2002

1 reference

30 December 2023

32

86

399

A Palumbo

2001

1 reference

30 December 2023

43

59

2615

J Adams

1999

1 reference

30 December 2023

Identifiers

DOI

10.1007/BF02983778

1 reference

6 August 2017

1 reference